Alnylam Pharmaceuticals, Inc Forecast, price target & analysts
Alnylam Pharmaceuticals, Inc Target price 2025 - Analyst rating & recommendation
Alnylam Pharmaceuticals, Inc Classifications & Recommendation:
Alnylam Pharmaceuticals, Inc Price Target
| Target Price | $483.48 |
| Price | $452.74 |
| Potential |
6.79%
register free of charge
|
| Number of Estimates | 29 |
|
29 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2026 .
The average Alnylam Pharmaceuticals, Inc target price is $483.48.
This is
6.79%
register free of charge
$598.50
32.20%
register free of charge
$238.36
47.35%
register free of charge
|
|
| A rating was issued by 36 analysts: 27 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2026 of
6.79%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.25 | 3.72 |
| 22.97% | 65.55% | |
| EBITDA Margin | -5.35% | 12.99% |
| 57.15% | 342.95% | |
| Net Margin | -12.37% | 5.12% |
| 48.62% | 141.38% |
33 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2025. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2025. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.18 | 1.46 |
| 38.07% | 166.97% | |
| P/E | 310.43 | |
| EV/Sales | 15.55 |
32 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 10 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
